Business Wire

IBS Recognizes Temenos as the #1 Best-Selling Banking Software for Digital, Core Banking, Payments, and Risk Management

16.6.2020 10:07:00 EEST | Business Wire | Press release

Share

Intelligence Sales League Table 2020 (SLT). Temenos was also named a regional leader in both Europe and Americas. Temenos, with its AI and advanced cloud technology, continues to be the undisputed leader in the main product categories in the IBS League Table with the greatest number of competitors.

Temenos has been ranked as the best-selling core banking system for 15 years, as well as the best-selling vendor for digital banking for the fourth consecutive year. For 21 years running, Temenos has demonstrated consistent leadership, placing in the top two positions for core banking systems. In this year’s Sales League Table, Temenos led in nine categories, including:

  • #1 Digital banking and channels with Temenos Infinity, gaining 38 new name deals
  • #1 Best-selling core banking system with Temenos Transact, securing 51 new name customer deals
  • #1 Retail payments system with 51 new deals for Temenos Payments
  • #1 Risk management system, closing 53 new deals with Temenos Financial Crime Mitigation
  • #1 Regional Leader in Europe, working with ABN AMRO and challenger banks such as Lunar and Alba
  • #1 Regional Leader in Americas, partnering with innovative banks such as CWB Financial Group
  • #2 Regional Leader in the Middle-East and Africa with key clients such as Egyptian National Post Organization
  • #2 Regional Leader in APAC with innovative clients such as TSB with Temenos Infinity Digital Onboarding and Virgin Money Australia
  • #2 Islamic Banking, partnering with the world's largest Islamic bank, Al Rajhi Bank

Max Chuard, Chief Executive Officer, Temenos, said: “It’s a great honor to be recognized as the best-selling banking software provider with the most modern technology across the main product categories of digital, core banking, retail payments, and risk management systems. Now more than ever we see an acceleration in digital and cloud adoption – banks need agile, modern banking technology across the front and back office. We offer our offer our clients, both established banks and new entrants, the winning combination of the richest banking functionality and the most advanced cloud-native, cloud-agnostic technology. We deliver solutions for the ‘New Normal’ that give our clients agility, speed to market, hyper-personalized services at the front end and automation and operational excellence in the back office. The IBS report reconfirms Temenos as global powerhouse and the world’s #1 banking software company and I would like to thank our customers, partners and employees for helping us achieve this exciting milestone.”

IBS’ Sales League Table Panel, said: “2019 was a record-breaking year for our Sales League Table, with nearly 900 validated deals globally and the highest level of vendor participation to-date. Temenos’ success was notable due to achieving #1 positions in the most intensely competitive categories including digital banking, core banking, retail payments and risk management systems. At IBS Intelligence, we are seeing banks re-visiting their digital transformation plans to support their businesses through the current COVID-19 crisis. 2020 will be an interesting year for our industry and we will be continuing to track new deals and trends to support our clients worldwide.”

Temenos continues to relentlessly focus on innovation, investing 20% of its revenue in R&D – more than any other provider in the industry. The IBS Intelligence Sales League Table is the global barometer for sales performance of banking platforms ranging from retail, to private, to Islamic, to digital-only and universal banking. The SLT provides a vital tool to executives in banks for selecting vendors for RFIs and influences vendor selection across conventional and digital banking.

– Ends –

About Temenos

Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.

Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.

For more information, please visit www.temenos.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts
Jessica Wolfe & Grace Collins
Temenos Global Public Relations
Tel: +1 610 232 2793 & + 44 20 7423 3969
Email : press@temenos.com

Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email: allnewgatetemenos@newgatecomms.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye